The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on NBIX. Neurocrine Biosciences, Inc.'s share was trading at $159.76 as of June 12th. NBIX’s trailing and forward P/E were 24.58 and 22.57 respectively according to Yahoo Finance.

Likoper/Shutterstock.com

Neurocrine Biosciences, Inc. (NBIX) is a San Diego-based biopharmaceutical company focused on central nervous system, neurological, psychiatric, and endocrine disorders, positioned to benefit from rising demand in central nervous system therapeutics as aging populations and broader insurance coverage expand diagnosis and treatment of brain-related conditions.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Neurocrine Biosciences’ flagship therapy Ingrezza (valbenazine), a treatment for tardive dyskinesia, continues to anchor growth, with significant room for expansion as many eligible patients remain untreated and prescription penetration increases across the U.S. psychiatric care system. Momentum is supported by successful launch of Crenessity (crinecerfont) for congenital adrenal hyperplasia, adding diversification beyond its core neurology franchise.

Importantly, Neurocrine Biosciences is advancing late-stage pipeline programs, including Phase 3 (Phase 3 clinical trials) candidates in major depressive disorder and schizophrenia, large underserved markets with meaningful commercial upside if successfully developed and approved. The broader central nervous system landscape is experiencing renewed investor interest as pharmaceutical peers increase research and development and partnership activity in psychiatric and neurological disorders, reinforcing long-term sector tailwinds.

On the technical side, recent price action shows improving momentum, with a confirmation bar forming alongside rising volume and price moving into a momentum zone, indicating buyers are gaining conviction while selling pressure is easing. This setup reflects early trend continuation when supported by fundamental catalysts.

Combined with a strong commercial base, expanding pipeline optionality, and favorable industry dynamics, Neurocrine Biosciences is positioned as a high-quality central nervous system growth platform with multiple drivers for sustained upside potential over the medium to long term, supported by execution and continued clinical and commercial expansion.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG by MADD-Scientis in March 2025, which highlighted Casgevy commercialization, strong net cash position, pipeline optionality, and a potential ~230% upside under conservative assumptions. CRSP’s stock price has appreciated by approximately 21.55% since our coverage. TradersPro’s Substack shares a similar view but emphasizes Neurocrine Biosciences’ central nervous system commercial strength and late-stage depression and schizophrenia pipeline as the key growth drivers.

Neurocrine Biosciences, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 53 hedge fund portfolios held NBIX at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the risk and potential of NBIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NBIX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.